To perform a pilot study on patients with progressive G2/3 glioma after treatment with radiotherapy and chemotherapy, who consent to resection of tissue for molecular typing or analysis of tissue resected at surgery within six months prior to enrolment, with a view of treatment with matched targeted agents where available, or else treatment with standard of care therapies.

HMRC Clinical Trials Centre (CTC), University of Sydney0 sites10 target enrollmentFebruary 3, 2020

ConditionsGrade 2 glioma (low grade)Grade 3 glioma (intermediate grade)Cancer - Brain

Overview

Phase: 未知
Intervention: Not specified
Conditions: Grade 2 glioma (low grade)
Sponsor: HMRC Clinical Trials Centre (CTC), University of Sydney
Enrollment: 10
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

February 3, 2020

End Date

May 31, 2021

Last Updated

2 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

HMRC Clinical Trials Centre (CTC), University of Sydney

Eligibility Criteria

Inclusion Criteria

•1\. Adults, aged 18 years and older, with histological confirmed grade 2 or 3 glioma at initial diagnosis.
•2\. Prior to last craniotomy and surgery, evidence of progressive disease as defined as evidence of new contrast\-enhancing tumour and/or 25% increase in the size of the T2/FLAIR area compared to prior imaging after prior treatment with radiotherapy and chemotherapy.
•3\. Has available tissue from resection for progressive disease for molecular profiling either within 6 months of study enrolment or following enrolment.
•4\. For patients who are undergoing standard of care surgery at the time of study entry:
•a. The patient must be suitable for craniotomy as the opinion of the neurosurgical team who will perform the surgery.
•b. In the opinion of the neurosurgical team, it will be possible to safely undertake a debulking procedure and that sufficient tissue will be obtained for molecular testing
•c. Has substantially recovered from their surgical resection, as evidenced by having no major on\-going safety issues (e.g. infection requiring antibiotics)
•5\. Patients who have already undergone standard of care surgery less than or equal to 6 months prior to study registration, there must be sufficient tissue available for molecular testing and the patient must not have had intervening anti\-cancer therapy.
•6\. Dose at registration must be less than or equal to 20mg prednisolone or less than or equal to 3 mg dexamethasone daily (or equivalent). Patients who are not on steroids are preferred for study participation.
•7\. ECOG performance status 0\-2\.

Exclusion Criteria

•1\. Glioma tissue for molecular pathology obtained greater than or equal to 6 months prior to study entry
•2\. Any intervening systemic therapy or radiotherapy between most recent imaging showing progressive disease and study enrolment
•3\. Patients who have had intra\-surgical treatments (e.g. oncolytic virus administration, Gliadel wafers) at their last craniotomy prior to study enrolment
•4\. Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results.
•5\. Subjects unable (e.g. due to pacemaker or ICD device) or unwilling to have a contrast\-enhanced MRI of the head.
•6\. Serious medical or psychiatric conditions that might limit the ability of the patient to comply with the protocol.